Single-dose malaria drug cabamiquine shows early trial promise

A new malaria candidate designed for single-dose treatment has produced early clinical results that researchers say could simplify one of global health’s most logistically difficult drug regimens. According to The Independent, scientists at the University of Dundee discovered an antimalarial compound called cabamiquine and tested it in combination with the existing drug pyronaridine, with initial findings published in The Lancet Infectious Diseases.

The promise is operational as much as pharmacological. Malaria treatment in many endemic settings is built around patients returning for multiple doses, clinics maintaining reliable stocks, and health workers managing adherence while resistance pressures keep rising. The Independent cites 2024 estimates of 282 million malaria cases and 610,000 deaths, with increasing numbers partly attributed to drug resistance. A regimen that can be delivered once—rather than over several days—reduces the number of failure points: fewer missed doses, fewer follow-up visits, and less scope for partial treatment that can select for hardier parasites.

In the early-stage trial described by The Independent, cabamiquine plus pyronaridine was effective and showed a favourable safety profile in adults and teenagers. The results are not presented as a finished product: the reporting emphasises that the combined therapy now needs larger trials and testing in children, who bear a large share of malaria’s burden. The work also illustrates how modern antimalarial development is stitched together across institutions: the Dundee team led the discovery effort, while the trial was conducted by Merck as part of the PAMAfrica consortium, and the programme drew support from Medicines for Malaria Venture (MMV). Co-funding came via the EDCTP2 Programme with support from the European Union and the Swedish International Development Co-operation Agency, a reminder that drug candidates for low-income markets often rely on public and philanthropic finance long before commercial demand is clear.

Dundee researcher Beatriz Baragana told The Independent that cabamiquine could simplify dosing regimens, and the head of Dundee’s drug discovery unit, Ian Gilbert, framed single-dose delivery as particularly relevant where healthcare delivery is difficult. MMV said it plans to progress the cabamiquine–pyronaridine combination further, with MMV’s Paul Willis pointing to the need for new treatment and prevention options that are easier to administer.

For now, the key data point is still modest: a new molecule has cleared an early clinical hurdle, and the next test is whether the one-dose idea survives the move from controlled trials to the places where malaria is treated in practice.